AR078047A1 - Inmunoglobulinas - Google Patents
InmunoglobulinasInfo
- Publication number
- AR078047A1 AR078047A1 ARP100101814A ARP100101814A AR078047A1 AR 078047 A1 AR078047 A1 AR 078047A1 AR P100101814 A ARP100101814 A AR P100101814A AR P100101814 A ARP100101814 A AR P100101814A AR 078047 A1 AR078047 A1 AR 078047A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding proteins
- immunoglobulins
- antigen
- mabdab
- ipf
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18183309P | 2009-05-28 | 2009-05-28 | |
| US28893009P | 2009-12-22 | 2009-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078047A1 true AR078047A1 (es) | 2011-10-12 |
Family
ID=42335086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101814A AR078047A1 (es) | 2009-05-28 | 2010-05-26 | Inmunoglobulinas |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20100303821A1 (enExample) |
| EP (1) | EP2435481A1 (enExample) |
| JP (1) | JP5919188B2 (enExample) |
| KR (1) | KR20120034679A (enExample) |
| CN (1) | CN102459341A (enExample) |
| AR (1) | AR078047A1 (enExample) |
| AU (1) | AU2010251955A1 (enExample) |
| BR (1) | BRPI1016061A2 (enExample) |
| CA (1) | CA2763443A1 (enExample) |
| CO (1) | CO6400150A2 (enExample) |
| CR (1) | CR20110664A (enExample) |
| DO (1) | DOP2011000347A (enExample) |
| EA (1) | EA201190275A1 (enExample) |
| IL (1) | IL216261A0 (enExample) |
| MA (1) | MA33381B1 (enExample) |
| MX (1) | MX2011012622A (enExample) |
| PE (1) | PE20120401A1 (enExample) |
| SG (1) | SG176203A1 (enExample) |
| TW (1) | TW201107345A (enExample) |
| UY (1) | UY32664A (enExample) |
| WO (1) | WO2010136481A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| WO2010096486A1 (en) | 2009-02-17 | 2010-08-26 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| AU2010251955A1 (en) | 2009-05-28 | 2011-12-22 | Glaxo Group Limited | IL-13 binding protein |
| EP2506876B1 (en) | 2009-12-02 | 2016-10-12 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| CN113156139A (zh) * | 2013-01-03 | 2021-07-23 | 梅索磅秤技术有限公司 | 测定实验对象组 |
| CA2905223A1 (en) * | 2013-04-05 | 2014-10-09 | Genentech, Inc. | Anti-il-4 antibodies and bispecific antibodies and uses thereof |
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| US9840553B2 (en) * | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016054114A1 (en) * | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions |
| RU2765242C2 (ru) | 2015-08-07 | 2022-01-27 | Имаджинаб, Инк. | Антигенсвязывающие конструкции против молекул-мишеней |
| MA43025A (fr) * | 2015-10-02 | 2021-05-26 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3 |
| SI3448391T1 (sl) | 2016-04-27 | 2024-08-30 | AbbVie Manufacturing Management Unlimited Company | Metode zdravljenja bolezni, pri katerih je aktivnost il-13 škodljiva, z uporabo protiteles anti-il-13 |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| CN118005784A (zh) * | 2022-11-08 | 2024-05-10 | 上海洛启生物医药技术有限公司 | 抗il-13长效纳米抗体序列及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
| WO2003092610A2 (en) | 2002-05-01 | 2003-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat hiv infection and aids |
| GB0414799D0 (en) * | 2004-07-01 | 2004-08-04 | Glaxo Group Ltd | Immunoglobulins |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| GB0600488D0 (en) | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| CA2640066A1 (en) * | 2006-01-24 | 2007-08-02 | Roland Beckmann | Fusion proteins that contain natural junctions |
| WO2007085815A2 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind il-4 and/or il-13 |
| AU2008328726B2 (en) | 2007-11-30 | 2014-06-12 | Glaxo Group Limited | Antigen-binding constructs |
| CA2718120A1 (en) | 2008-03-31 | 2009-10-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
| AU2010251955A1 (en) | 2009-05-28 | 2011-12-22 | Glaxo Group Limited | IL-13 binding protein |
-
2010
- 2010-05-26 AU AU2010251955A patent/AU2010251955A1/en not_active Abandoned
- 2010-05-26 EA EA201190275A patent/EA201190275A1/ru unknown
- 2010-05-26 US US12/787,588 patent/US20100303821A1/en not_active Abandoned
- 2010-05-26 BR BRPI1016061A patent/BRPI1016061A2/pt not_active IP Right Cessation
- 2010-05-26 AR ARP100101814A patent/AR078047A1/es not_active Application Discontinuation
- 2010-05-26 MA MA34479A patent/MA33381B1/fr unknown
- 2010-05-26 JP JP2012512352A patent/JP5919188B2/ja not_active Expired - Fee Related
- 2010-05-26 WO PCT/EP2010/057228 patent/WO2010136481A1/en not_active Ceased
- 2010-05-26 US US13/321,982 patent/US8680245B2/en not_active Expired - Fee Related
- 2010-05-26 MX MX2011012622A patent/MX2011012622A/es not_active Application Discontinuation
- 2010-05-26 SG SG2011086410A patent/SG176203A1/en unknown
- 2010-05-26 CA CA2763443A patent/CA2763443A1/en not_active Abandoned
- 2010-05-26 EP EP10722076A patent/EP2435481A1/en not_active Withdrawn
- 2010-05-26 TW TW099116859A patent/TW201107345A/zh unknown
- 2010-05-26 CN CN2010800337231A patent/CN102459341A/zh active Pending
- 2010-05-26 PE PE2011002022A patent/PE20120401A1/es not_active Application Discontinuation
- 2010-05-26 UY UY0001032664A patent/UY32664A/es unknown
- 2010-05-26 KR KR1020117031392A patent/KR20120034679A/ko not_active Withdrawn
-
2011
- 2011-11-10 IL IL216261A patent/IL216261A0/en unknown
- 2011-11-11 DO DO2011000347A patent/DOP2011000347A/es unknown
- 2011-11-25 CO CO11162427A patent/CO6400150A2/es not_active Application Discontinuation
- 2011-12-09 CR CR20110664A patent/CR20110664A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5919188B2 (ja) | 2016-05-18 |
| EA201190275A1 (ru) | 2012-11-30 |
| DOP2011000347A (es) | 2012-01-15 |
| TW201107345A (en) | 2011-03-01 |
| US20120082682A1 (en) | 2012-04-05 |
| JP2012528110A (ja) | 2012-11-12 |
| CR20110664A (es) | 2012-02-27 |
| SG176203A1 (en) | 2011-12-29 |
| EP2435481A1 (en) | 2012-04-04 |
| CO6400150A2 (es) | 2012-03-15 |
| CN102459341A (zh) | 2012-05-16 |
| IL216261A0 (en) | 2012-01-31 |
| WO2010136481A1 (en) | 2010-12-02 |
| MA33381B1 (fr) | 2012-06-01 |
| MX2011012622A (es) | 2011-12-14 |
| US8680245B2 (en) | 2014-03-25 |
| UY32664A (es) | 2010-12-31 |
| CA2763443A1 (en) | 2010-12-02 |
| PE20120401A1 (es) | 2012-05-04 |
| AU2010251955A1 (en) | 2011-12-22 |
| KR20120034679A (ko) | 2012-04-12 |
| BRPI1016061A2 (pt) | 2016-09-13 |
| US20100303821A1 (en) | 2010-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078047A1 (es) | Inmunoglobulinas | |
| UY32341A (es) | Proteínas de unión antígeno novedosas | |
| CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
| UY33421A (es) | Proteinas de union al antígeno humanizados | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| AR076655A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
| EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
| CL2013000930A1 (es) | Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17. | |
| CL2011002482A1 (es) | Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer | |
| CO6531489A2 (es) | Anticuerpo anti -tslp modificado por técnicas de ingenieria genética | |
| CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
| CR20120404A (es) | Proteinas de enlace cd127 | |
| CR20110152A (es) | Anticuerpos anti-il-13 modificados, composiciones, métodos y usos | |
| EA201492149A8 (ru) | St2-антигенсвязывающие белки | |
| PE20161327A1 (es) | Proteinas de enlace al antigeno il-23 humana | |
| HUE053489T2 (hu) | Az anti-il-13 antitestek izolálása és tisztítása a protein A affinitás kromatográviával | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| EA201401204A1 (ru) | Антитела к il-23p19 | |
| CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| CL2011002831A1 (es) | Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo. | |
| BR112012021329A2 (pt) | anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo. | |
| EA201591133A1 (ru) | СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19 | |
| UA123202C2 (uk) | Антитіло до тау-білка і його застосування |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |